Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice
SCT1000 elicited robust, durable, and consistent humoral immune responses across all 14 HPV types, indicating its potential as a broad-spectrum vaccine candidate against HPV types 6/11/16/18/31/33/35/39/45/51/52/56/58/59. The significant correlations observed between PBNA and total IgG LIA support the use of the Luminex-based total IgG method as a reliable and effective alternative for immunogenicity assessment in preclinical and future clinical vaccine development.
Authors
- Jianbo Lu
- Hongbin Qiu (ORCID: https://orcid.org/0000-0002-6709-2830)
- Shuman Gao
- Dan Meng (ORCID: https://orcid.org/0000-0001-8588-0235)
- Liangzhi Xie (ORCID: https://orcid.org/0000-0003-4504-7622)
- Siyu Liang
- Chun‐Xia Luo (ORCID: https://orcid.org/0000-0002-9840-0402)
- Lei Bei
- Xuefeng Li (ORCID: https://orcid.org/0000-0001-7707-4495)
- Yurong Wu
- Dandan Zhao (ORCID: https://orcid.org/0000-0002-6259-3871)
- Yajuan Kou
- Xiao Zhang (ORCID: https://orcid.org/0009-0002-9537-8120)
- Yang Wang (ORCID: https://orcid.org/0000-0003-2345-4729)
Institutions
- Jiamusi University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sinocelltech Group (China) (CN)
- Sino Biological (China) (CN)
Publication Details
- Journal
- Vaccines
- Published
- 2024-11-08
- DOI
- https://doi.org/10.3390/vaccines12111262
- Citations
- 3
- Primary Topic
- Cervical Cancer and HPV Research
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Beijing Science and Technology Planning Project